Evaluation and Management of Hyperandrogenism in Adult Women

Risk Stratification

• Testosterone levels >200 ng/dL (≈2–3 SD above normal) strongly suggest an androgen‑secreting neoplasm. 1
• Sudden onset or rapid progression of hyperandrogenic symptoms is a high‑risk feature warranting urgent work‑up. [2][3]
• Virilization signs (e.g., clitoromegaly, increased muscularity, deepening voice) indicate a high likelihood of neoplastic androgen excess. [3][4]
• Palpable abdominal or pelvic mass is another high‑risk indicator for an androgen‑producing tumor. 3
• Moderate‑to‑severe hirsutism (Ferriman‑Gallwey score > 15) places the patient in a moderate‑risk category. [2][4]
• Menstrual irregularity or amenorrhea is a moderate‑risk feature associated with hyperandrogenism. [1][5]
• Central obesity and acanthosis nigricans suggest underlying insulin resistance and moderate risk. [1][5]
• Infertility is also considered a moderate‑risk manifestation. [1][5]

Essential Laboratory Evaluation

• Obtain early‑morning (≈8 AM) fasting blood tests on cycle days 4–10 (if menstruating). This timing optimizes hormone measurement accuracy. [6][1]
• Measure total and free testosterone in a specialized reference laboratory to ensure reliable results. [6][5]
• Assess DHEAS to evaluate adrenal contribution to androgen excess. [1][5]
• Check 17‑hydroxyprogesterone (early‑morning, follicular phase) to rule out congenital adrenal hyperplasia, especially in high‑risk ethnic groups (e.g., Ashkenazi Jews ≈ 1:27, Hispanics ≈ 1:40, Slavics ≈ 1:50). [1][5]
• Measure prolactin to exclude hyperprolactinemia as a cause of menstrual disturbance. [1][5]
• Perform a pregnancy test in any patient with amenorrhea before initiating hormonal evaluation. [1][5]

Imaging Studies

• Pelvic ultrasonography is mandatory to detect ovarian pathology: steroid‑cell tumors occur in ~0.2 % of hyperandrogenic women, with >50 % being malignant; it also identifies polycystic ovarian morphology and evaluates endometrial thickness. [4][5]
• High‑resolution adrenal CT is indicated when testosterone ≥200 ng/dL, DHEAS > 6,600 ng/mL, or when clinical suspicion points to an adrenal source. 1

Additional Endocrine Screening (when clinically indicated)

• Cushing’s syndrome: 24‑hour urinary free cortisol or overnight dexamethasone suppression test. 2
• Thyroid dysfunction: Serum TSH and free T4. 2
• Acromegaly: Serum IGF‑1 if clinical features are present. 5

Medication Review

• Exclude exogenous androgen exposure (e.g., anabolic steroids, androgenic supplements) especially in athletes or patients with conditions such as endometriosis. [5][3]
• Identify valproic acid as the only anticonvulsant known to raise testosterone levels. [6][5]
• Consider the impact of danazol on androgen levels. 4

Diagnostic Algorithm Based on Hormone Findings

• Markedly elevated testosterone (>200 ng/dL) with or without virilization:

• Moderately elevated testosterone with PCOS‑compatible features:

• Mildly elevated or normal testosterone with risk factors:

Critical Pitfalls to Avoid

• Do not assume ovarian origin solely because testosterone is high with normal DHEAS; rare pure testosterone‑secreting adrenal adenomas exist. 1
• Do not assume adrenal origin solely on the basis of elevated DHEAS; ovarian tumors can co‑secrete DHEAS. 1

Management Priorities

• Primary objective: Exclude an androgen‑secreting neoplasm and prevent morbidity from untreated PCOS‑related metabolic complications. [1][5]
• Recognize that PCOS increases risk for type 2 diabetes, metabolic syndrome, cardiovascular disease, and endometrial hyperplasia. [1][5]7
• After malignancy is ruled out, focus treatment on:

Management of Elevated DHEA‑S in Postmenopausal Women

Diagnostic Thresholds and Immediate Imaging

• In postmenopausal women with a DHEA‑S level > 600 µg/dL, high‑resolution adrenal CT should be performed without delay to rule out an androgen‑secreting adrenal cortical adenoma, as this concentration strongly predicts an adrenal source. 8

Hormonal Evaluation for Moderate Elevations (200–600 µg/dL)

• When DHEA‑S is moderately elevated (200–600 µg/dL), total and free testosterone must be measured in a specialized reference laboratory on an early‑morning, fasting sample to determine whether an additional androgen excess is present. 8
• If testosterone is normal or only mildly increased, clinicians should continue with a systematic hormonal and imaging work‑up rather than assuming a benign process. 8

Clinical Assessment for Mild Elevations (<200 µg/dL)

• For DHEA‑S values below 200 µg/dL, patients should be evaluated for overt signs of hyperandrogenism—such as hirsutism, acne, or virilization—because even modest biochemical elevations can be clinically relevant. (American College of Endocrinology & American Association of Clinical Endocrinologists) [9][10]

Imaging Indications

• Adrenal CT is mandated whenever DHEA‑S exceeds 600 µg/dL, regardless of other hormone levels, as this absolute threshold signals a high likelihood of an adrenal neoplasm. 8

Diagnostic Guidelines for Severe Virilization without Acne (Cited Evidence)

Hormonal Assessment

• Total testosterone measurement is the first‑line test for evaluating hyperandrogenism in women. 11
• DHEAS measurement should be performed to differentiate adrenal from ovarian sources of excess androgen. 11

Interpretation of Hormone Levels

• A DHEAS level exceeding 600 µg/dL (≈6600 ng/mL) strongly suggests an androgen‑secreting adrenal cortical adenoma. 11
• When total testosterone is more than twice the upper limit of normal while DHEAS is normal, ovarian hyperthecosis should be considered. 11
• Ovarian hyperthecosis is typically associated with insulin resistance. 11

Imaging Recommendations

• Pelvic ultrasound is recommended to search for ovarian hyperthecosis or occult ovarian tumors in cases of moderately elevated testosterone with normal DHEAS. 11

Diagnostic Value of Normal DHEAS with Elevated Testosterone

Hormonal Differentiation

• In patients presenting with male‑range testosterone levels, a normal DHEAS concentration (below the assay‑specific upper limit) strongly suggests an ovarian source of androgen excess rather than an adrenal origin. This observation is supported by evidence published in The Journal of Clinical Endocrinology & Metabolism (2008) and is considered a reliable diagnostic indicator. 12

Non‑tumoral Causes of Overt Virilization in Women

Overview of Major Non‑tumoral Etiologies

• In women with clear‑cut virilization, the principal non‑tumoral causes are non‑classic congenital adrenal hyperplasia, ovarian hyperthecosis, Cushing syndrome, hyperprolactinemia, and exogenous or medication‑related androgen exposure. 13

Endocrine Disorders

Congenital Adrenal Hyperplasia (Non‑classic)

• (No directly cited fact with a citation; omitted.)

Ovarian Hyperthecosis

• (No directly cited fact with a citation; omitted.)

Cushing Syndrome

• Hypercortisolism should be considered a potential source of androgen excess, although patients usually display the classic clinical features of Cushing syndrome. 13

Hyperprolactinemia

• Elevated prolactin can produce androgen excess with menstrual disturbances, but affected individuals typically also show other prolactin‑related signs such as galactorrhea or headaches. 13

Other Endocrinopathies

• Acromegaly and thyroid dysfunctions, although rare as primary causes of virilization, must be kept in mind during evaluation. 13

Iatrogenic and Exogenous Androgen Exposure

Anabolic Steroids and Other Exogenous Androgens

• Systematic inquiry for the use of anabolic steroids or other exogenous androgens is essential, especially in athletic populations. [14][13]
• Standard laboratory assays do not detect these agents, making a detailed medication history crucial. 14

Androgenic Medications

• Danazol is a known androgenic drug that can induce virilization. [14][13]
• Valproic acid is the only anticonvulsant recognized to raise testosterone levels and should be considered in the work‑up. [14][13]

Polycystic Ovary Syndrome (Severe Phenotype)

• While PCOS is the most frequent cause of hyperandrogenism in pre‑menopausal women, the presence of true virilization signs (clitoromegaly, increased muscle bulk, deepening of voice) markedly raises the likelihood of an androgen‑secreting tumor. [14][13]

Diagnostic Pitfalls

• Failure to obtain a thorough medication history can miss exogenous androgen exposure, because such agents are not identified by routine hormonal assays. [14][13]
• Even when hormone levels are only moderately elevated, overt virilization mandates comprehensive investigation—including imaging—to exclude a moderately secreting tumor. [14][13]

Clinical Considerations

• Rapid onset or quick progression of virilization increases the probability of a secreting tumor, yet non‑tumoral causes remain possible. [14][13]
• Typical signs of virilization include clitoromegaly, increased muscle mass, voice deepening, androgenic alopecia, and breast atrophy. 14
• Imaging studies (pelvic ultrasound and adrenal CT) are indispensable even when a non‑tumoral etiology is suspected, because tumors may present with indolent clinical courses. 14

Management of Androgen‑Secreting Adrenal Tumors

Surgical Treatment Recommendations

• Serum androgen testing should be obtained in any patient with a hormone‑secreting adrenal mass or clinical signs of virilization to confirm excess androgen production. 15
• Adrenalectomy is indicated for adrenal tumors that are biochemically active (i.e., produce excess androgens). 15
• When feasible, a minimally‑invasive surgical approach (laparoscopic or robotic) is preferred for resection of hormone‑secreting adrenal lesions. 15
• Open adrenalectomy should be considered for large adrenocortical carcinomas or tumors with local invasion, where minimally‑invasive techniques may be insufficient. 15

Multidisciplinary Care

• A low threshold for multidisciplinary review (endocrinology, surgery, radiology) is recommended when imaging findings are atypical, there is evidence of hormone hypersecretion, or adrenal surgery is being contemplated. 15

Urgent Evaluation and Management of Severe Virilisation without Acne

Urgent endocrine assessment

• The American College of Endocrinology and the American Association of Clinical Endocrinologists recommend that women who present with marked virilisation (deep voice, clitoromegaly, increased male‑type muscle bulk, severe hirsutism) but no acne undergo an urgent endocrine work‑up to exclude an androgen‑secreting tumour, because > 50 % of such tumours are malignant. 16

Clinical indicators of hyperandrogenism

• Clitoromegaly is identified as a cardinal sign of severe hyperandrogenism in affected women. 16
• A deep, masculine voice is a characteristic manifestation of virilisation in this population. 16
• Development of male‑pattern muscle bulk signals significant androgen excess in women with severe virilisation. 16
• Androgenic alopecia (including temporal hair loss) is a frequent cutaneous sign of hyperandrogenism. 16
• Breast atrophy may be observed as part of the virilisation syndrome. 16
• A masculine habitus can develop after prolonged androgen exposure in these patients. 16
• The absence of acne does not reduce the probability of an underlying androgen‑secreting tumour in women with overt virilisation. 16

Metabolic assessment

• A fasting glucose‑to‑insulin ratio < 4.5 indicates insulin resistance in hyperandrogenic women and should be evaluated as part of the metabolic work‑up. 17

Pharmacologic treatment of glucocorticoid‑suppressible adrenal hyperandrogenism

• For adrenal hyperandrogenism that is glucocorticoid‑suppressible, the American College of Endocrinology and the American Association of Clinical Endocrinologists advise low‑dose glucocorticoid therapy (dexamethasone 0.25–0.5 mg nightly or prednisone 5–7.5 mg nightly) for 2–3 months, which leads to a progressive decline in androgen levels after normalisation; patients should be monitored every 3–4 months for one year. 18

First‑line therapy for severe PCOS‑related hyperandrogenism (after tumour exclusion)

• Combined oral contraceptives are recommended as first‑line treatment to regulate menstrual cycles and suppress androgen production in women with severe polycystic ovary syndrome. 19
• Additional evidence supports the use of combined oral contraceptives as the preferred initial therapy for severe PCOS‑related hyperandrogenism. 20

Postmenopausal Persistence of PCOS‑Related Hyperandrogenism

Hormonal Profile in Postmenopausal Women with Prior PCOS

• In women who had polycystic ovary syndrome before menopause, circulating testosterone levels remain relatively higher after menopause compared with women without prior PCOS, indicating that the postmenopausal ovary continues to produce androgens despite the loss of ovarian estrogen production. 21

• These women also exhibit a reduced estrogen‑to‑androgen ratio after menopause, reflecting a persistent imbalance that may contribute to metabolic and cardiovascular risk. 21

Assessment and Interpretation of Free Testosterone in Women

Laboratory Assessment

• Free testosterone is more sensitive than total testosterone for detecting subtle androgen excess because it reflects variations in sex‑hormone‑binding globulin (SHBG). The Endocrine Society highlights this advantage of free testosterone measurement. 22
• Commercial laboratories often yield inaccurate testosterone results in women due to poor assay sensitivity at low concentrations and unreliable reference intervals; therefore, specialized reference laboratories that employ validated methods such as tandem mass spectrometry or equilibrium dialysis are essential for accurate assessment. The American College of Endocrinology recommends using these specialized assays. [22][23]
• When moderate‑to‑severe hirsutism, persistent acne, menstrual irregularities, or other hyperandrogenic signs are present despite a “normal” free testosterone, the measurement should be repeated in a specialized laboratory using liquid chromatography‑tandem mass spectrometry (LC‑MS/MS) or equilibrium dialysis to confirm the result. The Endocrine Society advises this confirmatory testing. [22][23]
• Prolactin and thyroid‑stimulating hormone (TSH) should be measured to exclude hyperprolactinemia and thyroid dysfunction as alternative causes of menstrual disturbance. The American College of Endocrinology includes these tests in the initial hormonal panel. 23

Clinical Evaluation of Hyperandrogenism

• Hirsutism should be quantified with the Ferriman‑Gallwey score; a score ≥ 4–6 (ethnicity‑adjusted) indicates clinically significant hirsutism, while a score > 15 denotes moderate‑to‑severe disease. The American College of Endocrinology provides these cut‑offs. 24
• Persistent acne that extends beyond the late teens and is resistant to standard dermatologic therapy—especially when accompanied by menstrual irregularities—warrants evaluation for underlying hyperandrogenism. The American College of Endocrinology notes this clinical cue. 24
• Oligomenorrhea (cycles > 35 days or < 8 cycles/year) or amenorrhea (absence of menses ≥ 3 months) in the presence of hyperandrogenic signs suggests polycystic ovary syndrome (PCOS) or other androgen disorders. The American College of Endocrinology cites these menstrual patterns as red flags. 24

Diagnostic Pitfalls

• A single free testosterone value of 5.2 pg/mL should not be interpreted as normal when hyperandrogenic symptoms are present; assay variability and timing of sample collection can affect results. The Endocrine Society warns against reliance on a solitary measurement. [22][23]
• Routine commercial laboratory testosterone assays in women are unreliable because of systematic differences between assay platforms and overly broad normal ranges derived from populations that may include unrecognized androgen excess. The Endocrine Society recommends caution and use of specialized assays. [22][23]

Special Considerations for Women Over Age 35

• Women older than 35 years may exhibit clinical hyperandrogenism (e.g., hirsutism) without corresponding biochemical hyperandrogenemia because ovarian androgen production declines with age, yet the cutaneous manifestations persist; these patients still require monitoring for metabolic and cardiovascular sequelae. The Endocrine Society and the American College of Endocrinology emphasize the need for continued surveillance. [25][23]

Dynamic Endocrine Testing (When Initial Evaluation Is Inconclusive)

• If initial hormonal testing is equivocal, dynamic endocrine tests such as a low‑dose dexamethasone suppression test (to assess adrenal sources) or a GnRH‑agonist challenge (to assess ovarian sources) can help differentiate the origin of excess androgen production. The Endocrine Society recommends these provocative tests in ambiguous cases. 25

Guideline for Evaluation of Elevated DHEA‑S in Postmenopausal Women

Risk Stratification by DHEA‑S Level

• Critical elevation (DHEA‑S > 600 µg/dL ≈ 16 000 nmol/L) – Order an immediate high‑resolution adrenal CT because this concentration strongly predicts an androgen‑secreting adrenal cortical adenoma; urgent surgical evaluation is usually required. 26
• Critical elevation – Measure serum cortisol concurrently to screen for co‑existent hypercortisolism, which frequently accompanies adrenal adenomas that secrete excess DHEA‑S. 27
• Moderate elevation (200–600 µg/dL) – Obtain an 8 AM 17‑hydroxyprogesterone (17‑OHP) level to screen for non‑classic congenital adrenal hyperplasia (21‑hydroxylase deficiency), especially in high‑risk ethnic groups (e.g., Ashkenazi Jews ≈ 1:27, Hispanics ≈ 1:40, Slavics ≈ 1:50). 26
• Moderate elevation – Measure prolactin and thyroid‑stimulating hormone (TSH) to exclude hyperprolactinemia and thyroid dysfunction as alternative causes of androgen excess. 27
• Mild elevation (DHEA‑S < 200 µg/dL) – Perform a clinical assessment for hyperandrogenic signs (hirsutism, acne, androgenic alopecia, virilization) because even modest biochemical elevations can be clinically relevant. 28

Essential Hormonal Panel

• Total testosterone – Use a specialized LC‑MS/MS assay; values > 200 ng/dL strongly suggest an androgen‑secreting neoplasm and mandate immediate imaging of both adrenal glands and ovaries. 26
• Free testosterone – Preferred for detecting subtle androgen excess because it reflects variations in sex‑hormone‑binding globulin (SHBG). 26
• 17‑OHP – If the basal level exceeds 200 ng/dL, perform an ACTH stimulation test; a stimulated 17‑OHP > 1 000 ng/dL confirms non‑classic CAH. 29
• Prolactin – Routine measurement to rule out hyperprolactinemia as a cause of hormonal disturbance. 27
• TSH and free T4 – Evaluate thyroid function because thyroid disorders can alter androgen metabolism. 30
• Cortisol – Obtain a baseline level; if Cushing syndrome is suspected, add a 24‑hour urinary free cortisol or overnight dexamethasone suppression test. 29

Imaging Recommendations

• Adrenal CT (high‑resolution protocol) – Mandatory when DHEA‑S > 600 µg/dL, testosterone ≥ 200 ng/dL, or when clinical suspicion points to an adrenal source. 26
• Pelvic ultrasound – Indicated when testosterone is elevated with normal or only mildly elevated DHEA‑S to detect ovarian hyperthecosis or steroid‑cell tumors (≈ 0.2 % of hyperandrogenic women, > 50 % malignant). 31

Interpretation of Hormone Patterns

• Normal DHEA‑S with elevated testosterone – Suggests an ovarian source (e.g., ovarian hyperthecosis or tumor); proceed with pelvic ultrasound. 31
• Ovarian hyperthecosis – Typically associated with insulin resistance. 31
• Elevated DHEA‑S with normal testosterone – Points toward adrenal hyperandrogenism; measurement of DHEA (not just DHEA‑S) is useful because poorly differentiated adrenal tumors may secrete relatively more DHEA. 29
• Both DHEA‑S and testosterone markedly elevated – Indicates generalized androgen excess; simultaneous adrenal CT and pelvic ultrasound are recommended to localize the tumor. 26

Dynamic Testing (when initial work‑up is inconclusive)

• ACTH stimulation test – Administer 0.25 mg cosyntropin IV; measure cortisol and 17‑OHP at baseline and 60 min to detect 21‑hydroxylase deficiency or other steroidogenic defects. 28
• Two‑day low‑dose dexamethasone suppression test – After baseline pooled sampling, give dexamethasone 0.5 mg at lunch, dinner, and bedtime for 2 days; > 60 % suppression of DHEA‑S and > 40 % suppression of testosterone supports an adrenal source. 28
• GnRH agonist challenge – Rarely needed in postmenopausal women; used to assess residual ovarian androgen output when imaging is nondiagnostic. 28

Medication and Exogenous Androgen Review

• Valproic acid – The only anticonvulsant documented to raise testosterone levels. 27
• Drugs affecting SHBG – Thyroid hormones, tamoxifen, and raloxifene can artificially increase total testosterone without true hyperandrogenism; consider their impact when interpreting results. 31

Pitfalls to Avoid

• Do not delay imaging when DHEA‑S > 600 µg/dL or testosterone > 200 ng/dL; these thresholds mandate urgent evaluation for a hormone‑secreting neoplasm. 26
• Do not assume adrenal origin solely from an elevated DHEA‑S; ovarian tumors can co‑secrete DHEA‑S. 31
• Do not rely on a single testosterone measurement in the presence of hyperandrogenic signs; repeat testing in a specialized laboratory using validated assays. 27

Evidence strength was not explicitly stated in the source articles.